Welcome to our dedicated page for Arvinas news (Ticker: ARVN), a resource for investors and traders seeking the latest updates and insights on Arvinas stock.
Arvinas, Inc. (NASDAQ: ARVN) is a clinical-stage biotechnology company headquartered in New Haven, Connecticut and focused on targeted protein degradation. Its news flow centers on progress across a pipeline of investigational PROTAC (PROteolysis TArgeting Chimera) protein degraders for oncology and neurodegenerative disorders.
On this ARVN news page, readers can follow company-issued updates on key programs such as vepdegestrant, an investigational PROTAC estrogen receptor degrader for ER+/HER2- advanced or metastatic breast cancer with ESR1 mutations; ARV-393, a BCL6 degrader in Phase 1 trials for relapsed/refractory non-Hodgkin lymphoma; ARV-806, a KRAS G12D degrader for solid tumors including pancreatic, colorectal and lung cancer; and ARV-102, a LRRK2 degrader being studied in Parkinson’s disease and other neurodegenerative conditions.
Typical ARVN news items include clinical data presentations at major scientific meetings, regulatory milestones such as acceptance of the New Drug Application for vepdegestrant by the U.S. Food and Drug Administration, and preclinical results that characterize the activity of new PROTAC candidates. Arvinas also uses press releases to describe collaboration developments with Pfizer, organizational changes, financial updates and other corporate actions disclosed in its SEC filings.
Investors, clinicians and researchers can use this news feed to track how Arvinas’ PROTAC platform is being applied to targets like estrogen receptor, BCL6, KRAS G12D and LRRK2, and to monitor the timing and content of data readouts, regulatory events and partnership announcements related to ARVN.
Arvinas (NASDAQ: ARVN) reported Q2 2024 financial results and provided a corporate update. Key highlights include:
- Completed enrollment in VERITAC-3 Phase 3 trial lead-in for vepdegestrant in first-line ER+/HER2- metastatic breast cancer
- VERITAC-2 Phase 3 trial enrollment completion expected in Q4 2024, with topline data in Q4 2024/Q1 2025
- Received $150 million from Novartis for ARV-766 license and AR-V7 program sale
- Q2 revenue: $76.5 million, up from $54.5 million in Q2 2023
- Cash position: $1.23 billion as of June 30, 2024
- Sufficient funding into 2027
The company continues to advance its PROTAC protein degradation platform across multiple indications.
Arvinas (NASDAQ: ARVN) appoints Andrew Saik as Chief Financial Officer and Treasurer, effective June 24, 2024. Saik, an experienced biopharma finance executive, previously served as CFO at Intercept Pharmaceuticals where he led significant financial restructuring efforts. At Arvinas, he will focus on building financial systems and infrastructure necessary for transitioning to a commercial-stage biotech and managing ongoing clinical-stage programs. In connection with his appointment, Saik received an inducement grant of options to purchase 94,418 shares and a restricted stock unit for 61,409 shares, under Nasdaq Listing Rule 5635(c)(4).
Arvinas announced new preclinical data presentations for its investigational PROTAC® programs targeting BCL6 and LRRK2. The data were unveiled at the European Hematology Association 2024 Annual Congress and the Biennial International LRRK2 Meeting. Key findings for ARV-393, targeting BCL6, showed promising anti-tumor activity in B-cell lymphoma models. ARV-393 demonstrated potent BCL6 protein degradation and tumor growth inhibition in various diffuse large B-cell lymphoma (DLBCL) subtypes. Additionally, the LRRK2 degrader program highlighted significant potential in treating neurodegenerative diseases, showing effective LRRK2 degradation with a favorable safety profile compared to experimental inhibitors. Both ARV-393 and the oral PROTAC LRRK2 degrader, ARV-102, are currently in phase 1 clinical trials.
Arvinas announced two key promotions: Ian Taylor, Ph.D., is now President of Research and Development, while Angela Cacace, Ph.D., becomes Chief Scientific Officer.
Dr. Taylor has been with Arvinas since 2016, having held important roles at Bayer and Pfizer, and will oversee strategic inputs across Arvinas' pipeline. Dr. Cacace, joining in 2018, has over two decades of experience in neuroscience and oncology, and was pivotal in advancing Arvinas' PROTAC® technology, including ARV-102.
Both will report to CEO John Houston and lead further innovation and development within Arvinas, focusing on pioneering treatments in oncology and neuroscience.
Arvinas (Nasdaq: ARVN), a clinical-stage biotech company focusing on targeted protein degradation, announced participation in two prominent investor conferences. On June 6, 2024, John Houston, Ph.D., CEO and President, and Noah Berkowitz, M.D., Ph.D., CMO, will join a fireside chat at the Jefferies Global Healthcare Conference in NYC.
The team will also attend the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024, in Miami, featuring another fireside chat. Both events will be webcast live, accessible through Arvinas' website's Events + Presentations section.
Arvinas announced the acceptance of two abstracts for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Congress. The event will be held from May 31 to June 4, 2024, in Chicago. The first abstract features initial results from a Phase 1/2 study of ARV-766, a PROTAC androgen receptor degrader, in metastatic castration-resistant prostate cancer. It will be presented on June 3, 2024, from 1:15 p.m. to 2:45 p.m. CDT under the Genitourinary Cancer category.
The second abstract involves TACTIVE-K, a Phase 1b/2 study of vepdegestrant, a PROTAC estrogen receptor degrader, in combination with Pfizer's investigational CDK4 inhibitor, PF-07220060, in ER+/HER2- advanced breast cancer. This will be presented on June 2, 2024, from 9:00 a.m. to 12:00 p.m. CDT in the Breast Cancer—Metastatic category. Abstracts can be accessed on the official ASCO website.
Arvinas and Pfizer announced updated data from a Phase 1b trial evaluating vepdegestrant in combination with palbociclib (IBRANCE®). After six months of additional follow-up, the clinical benefit rate (63%), overall response rate (41.9%), and median progression-free survival (11.2 months) remained consistent with prior results. At the recommended Phase 3 dose of 200 mg, median progression-free survival reached 13.9 months. Significant reductions in circulating tumor DNA were observed, regardless of ESR1 gene mutation status. The safety profile was consistent with previous findings, with Grade 3/4 neutropenia (91%) being the most common adverse event. These results were presented at the 2024 ESMO Breast Cancer Annual Congress.
Arvinas, Inc. (ARVN) to present two posters with updated clinical trial data for vepdegestrant at the 2024 ESMO Breast Cancer Annual Congress in Berlin, Germany. Vepdegestrant is a novel investigational drug for ER+/HER2- breast cancer jointly developed with Pfizer. The presentations are scheduled for May 16, 2024, showcasing promising results.
Arvinas reported strong Q1 2024 financial results along with key corporate updates. The company continued enrollment in multiple clinical studies of vepdegestrant in metastatic breast cancer, progressed ARV-102 for neurodegenerative diseases, and entered a lucrative transaction with Novartis. The strategic deal includes an exclusive license for ARV-766 and sale of the preclinical AR-V7 program, with significant upfront payment and potential milestone payments. Arvinas also made key appointments in its management team and remains on track with its Phase 3 clinical programs. Financially, the company's cash position is strong, with enough funding to support planned operations until 2027.
Arvinas, Inc. (Nasdaq: ARVN) will be presenting at two investor conferences: the BofA Securities 2024 Healthcare Conference on May 14 and the UBS Spring Biotech Conferences on May 21. The company's Chief Medical Officer and Chief Business Officer will participate in various discussions and meetings.